Pieris Pharmaceuticals to Host Key Opinion Leader Event on February 6th
BOSTON, MA--(Marketwired - January 29, 2018) - Pieris Pharmaceuticals, Inc. (PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that it will host a Key Opinion Leader (KOL) Event in New York on Tuesday, February 6th from 8-10:30 AM EDT.
The KOL event will feature world-class thought leaders in immuno-oncology and respiratory diseases, followed by a company presentation. The event will include presentations from:
Michael A. Curran, PhD, Assistant Professor in the Department of Immunology and Scientific Director of the Oncology Research for Biologics and Immunotherapy Translation (ORBIT) platform at MD Anderson Cancer Center.
David H. Ilson, MD PhD, Medical Oncologist and Attending Physician at Memorial Sloan Kettering Cancer Center and Professor at Weill Cornell Medical College.
Gary Anderson, PhD, FThorSoc, FERS, Professor in the Medical Faculty at the University of Melbourne and Director of the Centre for Lung Health Research.
Bruce Levy, MD, Parker B. Francis Professor of Medicine at Brigham and Women's Hospital and the Chief of the Pulmonary and Critical Care Division.
The event will be accessible via a live webcast through this link beginning at 8am on February 6th.
In-person attendance is by invitation only. For more information please contact Clayton Robertson at crobertson@troutgroup.com.
About Pieris Pharmaceuticals
Pieris is a clinical-stage biotechnology company that discovers and develops Anticalin protein-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor microenvironment, an inhaled Anticalin protein to treat uncontrolled asthma and a half-life-optimized Anticalin protein to treat anemia. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Anticalin® is a registered trademark of Pieris. For more information, visit www.pieris.com.